WS #16598
AbbVie delivered a strong Q3 beat with revenue up 10.3% and raised full-year EPS guidance, offering a rare positive signal in the current earnings season. Conversely, Agios Pharmaceuticals fell 12% on an FDA review extension for Pyrukynd, and Medical Properties Trust was downgraded to Sell by RBC Capital, indicating that healthcare is bifurcating between strong pharma performers and regulatory/real estate risks.
Healthcare Earnings
AbbVie delivered a strong Q3 beat with revenue up 10.3% and raised full-year EPS guidance, offering a rare positive signal in the current earnings season. Conversely, Agios Pharmaceuticals fell 12% on an FDA review extension for Pyrukynd, and Medical Properties Trust was downgraded to Sell by RBC Capital, indicating that healthcare is bifurcating between strong pharma performers and regulatory/real estate risks.